Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned ...

Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...

Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March ...

Researchers studied the affect of comorbidities and medication use on survival in patients with cutaneous squamous cell carcinoma using immune checkpoint inhibitors.

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

A cutaneous horn is a type of growth that appears on the skin. It’s made of keratin, a protein that makes up the top layer of the skin. It may look like a cone or horn and can vary in size. The growth ...

Cutaneous leishmaniasis exhibits a wide spectrum of clinical presentations that is determined largely by the host immune response. The host immune response to infection is influenced both by host ...